Lyka Labs Limited (LYKALABS.NS)
INR 110.34
(-0.31%)
INR 110.34
(-0.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -24.89 Million INR | 81.07% |
| 2022 | -131.52 Million INR | -133.72% |
| 2021 | 389.99 Million INR | 486.49% |
| 2020 | -100.9 Million INR | 83.89% |
| 2019 | -626.2 Million INR | -1028.23% |
| 2018 | -55.5 Million INR | 67.87% |
| 2017 | -172.74 Million INR | -269.46% |
| 2016 | -46.75 Million INR | -226.82% |
| 2015 | 36.86 Million INR | 174.49% |
| 2014 | -49.49 Million INR | 24.89% |
| 2013 | -65.89 Million INR | -831.11% |
| 2012 | -7.07 Million INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 24.1 Million INR | 149.59% |
| 2009 | -48.62 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 14.4 Million INR | 167.68% |
| 2023 Q2 | -4.86 Million INR | 73.66% |
| 2023 FY | -24.89 Million INR | 81.07% |
| 2023 Q3 | 17.81 Million INR | 466.08% |
| 2023 Q1 | -18.46 Million INR | 38.36% |
| 2023 Q4 | -21.27 Million INR | -219.47% |
| 2022 Q3 | -105.21 Million INR | -2973.79% |
| 2022 Q2 | -3.42 Million INR | -157.5% |
| 2022 Q1 | 5.95 Million INR | 103.97% |
| 2022 FY | -131.52 Million INR | -133.72% |
| 2022 Q4 | -29.95 Million INR | 71.53% |
| 2021 Q3 | 60.85 Million INR | -78.6% |
| 2021 Q2 | 284.33 Million INR | 45.43% |
| 2021 Q1 | 195.5 Million INR | 1804.97% |
| 2021 FY | 389.99 Million INR | 486.49% |
| 2021 Q4 | -149.9 Million INR | -346.33% |
| 2020 Q2 | -57.49 Million INR | -22.99% |
| 2020 FY | -100.9 Million INR | 83.89% |
| 2020 Q3 | -22.65 Million INR | 60.6% |
| 2020 Q4 | 10.26 Million INR | 145.31% |
| 2020 Q1 | -46.74 Million INR | 63.98% |
| 2019 Q4 | -129.77 Million INR | 68.5% |
| 2019 Q1 | -31.65 Million INR | -140.66% |
| 2019 FY | -626.2 Million INR | -1028.23% |
| 2019 Q2 | -32.03 Million INR | -1.2% |
| 2019 Q3 | -411.95 Million INR | -1186.04% |
| 2018 Q2 | -64.56 Million INR | -15.19% |
| 2018 Q4 | 77.83 Million INR | 357.87% |
| 2018 FY | -55.5 Million INR | 67.87% |
| 2018 Q1 | -56.05 Million INR | 0.0% |
| 2018 Q3 | -30.18 Million INR | 53.25% |
| 2017 FY | -172.74 Million INR | -269.46% |
| 2016 Q1 | -41.36 Million INR | 60.46% |
| 2016 FY | -46.75 Million INR | -226.82% |
| 2016 Q4 | 18.41 Million INR | 163.98% |
| 2016 Q3 | -28.78 Million INR | -678.24% |
| 2016 Q2 | 4.97 Million INR | 112.03% |
| 2015 Q2 | 135.32 Million INR | 703.1% |
| 2015 Q4 | -104.62 Million INR | -2051.31% |
| 2015 Q3 | 5.36 Million INR | -96.04% |
| 2015 Q1 | 16.85 Million INR | 161.08% |
| 2015 FY | 36.86 Million INR | 174.49% |
| 2014 Q2 | 63.42 Million INR | 168.61% |
| 2014 Q1 | -92.44 Million INR | 0.0% |
| 2014 Q4 | -27.58 Million INR | 53.11% |
| 2014 Q3 | -58.83 Million INR | -192.76% |
| 2014 FY | -49.49 Million INR | 24.89% |
| 2013 Q3 | -95.37 Million INR | -215.25% |
| 2013 FY | -65.89 Million INR | -831.11% |
| 2013 Q1 | -24.66 Million INR | 66.86% |
| 2013 Q2 | -30.25 Million INR | -22.66% |
| 2012 Q2 | 4.14 Million INR | -56.41% |
| 2012 Q4 | -74.42 Million INR | -238.6% |
| 2012 Q3 | 53.69 Million INR | 1195.42% |
| 2012 FY | -7.07 Million INR | 0.0% |
| 2012 Q1 | 9.5 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2011 Q3 | -22.99 Million INR | 0.0% |
| 2010 FY | 24.1 Million INR | 149.59% |
| 2009 FY | -48.62 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biocon Limited | 10.22 Billion INR | 100.243% |
| Blue Jet Healthcare Limited | 1.63 Billion INR | 101.52% |
| Concord Biotech Limited | 3.08 Billion INR | 100.808% |
| Dishman Carbogen Amcis Limited | -1.53 Billion INR | 98.378% |
| Jubilant Ingrevia Limited | 1.82 Billion INR | 101.361% |
| Panacea Biotec Limited | -11.73 Million INR | -112.225% |
| Piramal Pharma Limited | 178.2 Million INR | 113.97% |
| SMS Lifesciences India Limited | 90.92 Million INR | 127.378% |
| Supriya Lifescience Limited | 1.19 Billion INR | 102.09% |
| Syngene International Limited | 5.1 Billion INR | 100.488% |
| TAKE Solutions Limited | -1.19 Billion INR | 97.919% |
| Zota Health Care Limited | -143.47 Million INR | 82.65% |